Xencor Gets CD20xCD3 Bispecific Back From J&J

Still Partnered On Two Antibodies

 
• By Joseph Haas
  
Return
J&J decided to return bispecific antibody plamotamab to Xencor • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business